ConductScience.org, home

Paper313402

An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D.

Zerwekh JE and 3 others. J Clin Endocrinol Metab, 1979. Cited by 63 papers, by iCite.

Cite this record

ConductScience Library. An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D. Papers, record 313402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/313402

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D.
PubMed
Journal
J Clin Endocrinol Metab
PubMed
Year
1979
PubMed
Publication types
Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
63
iCite
Relative citation ratio, by iCite
2.11
iCite
Revised in PubMed
2013-11-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zerwekh JEJ E
2Glass KK
3Jowsey JJ
4Pak CYC Y

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ErgocalciferolsMajor topic
HydroxycholecalciferolsMajor topic
OsteomalaciaMajor topic
Adult
Calcium
Female
Humans
Intestinal Absorption
Phosphates

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.

PMIDTitleJournalYearIn PapersSource
15128933Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15128933PubMed
6976436Vitamin D and hyperparathyroidism: the Lumleian Lecture 1981.J R Coll Physicians Lond1981https://conductscience.org/library/papers/6976436PubMed
6775776Tumoral calcinosis: evidence for concurrent defects in renal tubular phosphorus transport and in 1 alpha,25-dihydroxycholecalciferol synthesis.Calcif Tissue Int1980https://conductscience.org/library/papers/6775776PubMed
6770981Vitamin D-dependent rickets type II.Calcif Tissue Int1980https://conductscience.org/library/papers/6770981PubMed
6332830Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man.J Clin Invest1984https://conductscience.org/library/papers/6332830PubMed
6313754Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3.J Clin Invest1983https://conductscience.org/library/papers/6313754PubMed
6296200Resistance to 1,25-dihydroxyvitamin D. Association with heterogeneous defects in cultured skin fibroblasts.J Clin Invest1983https://conductscience.org/library/papers/6296200PubMed
6279228Failure to heal D-deficiency rickets and suppress secondary hyperparathyroidism with conventional doses of 1,25-dihydroxy vitamin D3.Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6279228PubMed
3937578Hypercalcemia associated with increased circulating 1,25 dihydroxyvitamin D in a patient with pulmonary tuberculosis.Calcif Tissue Int1985https://conductscience.org/library/papers/3937578PubMed
3872316Vitamin D-dependent rickets type II. Defective induction of 25-hydroxyvitamin D3-24-hydroxylase by 1,25-dihydroxyvitamin D3 in cultured skin fibroblasts.J Clin Invest1985https://conductscience.org/library/papers/3872316PubMed
3489007Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum concentration of 25-hydroxyvitamin D by increasing metabolic clearance rate.J Clin Invest1986https://conductscience.org/library/papers/3489007PubMed
3089562Bone in the marmoset: a resemblance to vitamin D-dependent rickets, type II.Calcif Tissue Int1986https://conductscience.org/library/papers/3089562PubMed
3024987Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D3 in a patient without alopecia.Eur J Pediatr1986https://conductscience.org/library/papers/3024987PubMed
3009551Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.J Clin Invest1986https://conductscience.org/library/papers/3009551PubMed
2991334Vitamin D-endocrine system.J Clin Invest1985https://conductscience.org/library/papers/2991334PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP2R1120227PubTator's text mininghttps://conductscience.org/library/genes/120227

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/313402

GET https://conductscience.org/api/papers/v1/313402/authors